Catalent, Inc. (CTLT)
| Market Cap | 11.52B |
| Revenue (ttm) | 4.42B |
| Net Income (ttm) | -413.00M |
| Shares Out | 181.51M |
| EPS (ttm) | -2.28 |
| PE Ratio | n/a |
| Forward PE | 50.15 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 13,674,041 |
| Open | 63.49 |
| Previous Close | 63.48 |
| Day's Range | 63.44 - 63.50 |
| 52-Week Range | 42.07 - 63.50 |
| Beta | 1.14 |
| Analysts | Hold |
| Price Target | 63.40 (-0.13%) |
| Earnings Date | Feb 7, 2025 |
About CTLT
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syring... [Read more]
Financial Performance
In 2024, Catalent's revenue was $4.38 billion, an increase of 2.77% compared to the previous year's $4.26 billion. Losses were -$1.04 billion, 307.4% more than in 2023.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for CTLT stock is "Hold." The 12-month stock price forecast is $63.4, which is a decrease of -0.13% from the latest price.
News
Lennox International Set to Join S&P 500 and BILL Holdings to Join S&P MidCap 400
NEW YORK , Dec. 18, 2024 /PRNewswire/ -- S&P MidCap 400 constituent Lennox International Inc. (NYSE: LII) will replace Catalent Inc. (NYSE: CTLT) in the S&P 500, and BILL Holdings Inc. (NYSE: BILL) wi...
Novo Holdings completes $16.5 bln takeover of Catalent
Novo Holdings has completed its $16.5 billion takeover of Catalent , the contract drug manufacturer announced on Wednesday, days after the companies said all regulatory closing conditions were fulfill...
Novo Holdings Completes Acquisition of Catalent
SOMERSET, N.J. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Catalent, Inc. (“Catalent”), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings A/S (...
Regulatory conditions on Novo Holdings' $16.5 bln Catalent deal fulfilled, companies say
All regulatory closing conditions related to Novo Holdings' $16.5 billion acquisition of U.S. contract drug maker Catalent had been fulfilled, the companies said on Saturday, adding that the transacti...
Novo Nordisk A/S: The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is cleared to close
Bagsværd, Denmark, 14 December 2024 — As of today, all regulatory closing conditions relating to the review of Novo Holdings A/S's pending acquisition of Catalent, Inc. (Catalent), including expiry of...
Catalent and Novo Holdings Fulfill All Regulatory Closing Conditions for Pending Transaction
SOMERSET, N.J. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Catalent, Inc. (“Catalent,” NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Ho...
The European Commission approves the acquisition of Catalent by Novo Holdings and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings
Bagsværd, Denmark, 6 December 2024 — Today, the European Commission approved Novo Holdings A/S' acquisition of Catalent, Inc. (Catalent), a global contract development and manufacturing organisation h...
Catalent and Novo Holdings Receive European Commission Unconditional Approval for Pending Transaction
SOMERSET, N.J. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Catalent, Inc. (“Catalent,” NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Ho...
Novo Holdings' $16.5 bln Catalent buy wins EU antitrust approval
Novo Holdings on Friday gained unconditional EU antitrust approval for its $16.5 bln acquisition of U.S. contract drug maker Catalent after EU regulators said they did not see any competition issues.
EU antitrust regulators set to okay $16.5 bln Novo Holdings, Catalent deal, source says
EU antitrust regulators are set to clear without conditions Novo Holdings' planned $16.5 billion takeover of Catalent , a person with direct knowledge of the matter said on Friday.
EU regulators quiz Novo Nordisk, Catalent rivals on $16.5 bln deal
EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' planned $16.5 billion takeover of Catalent , people familiar with the matt...
Catalent misses Q1 revenue estimates ahead of $16.5 bln deal close with Novo Holdings
Contract drug manufacturer Catalent , which is in the process of being acquired by Novo Holdings, posted a surprise first-quarter loss and revenue below Wall Street estimates on Tuesday.
Catalent, Inc. Reports First Quarter Fiscal 2025 Results
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced financial results for the f...
EU antitrust regulators to decide on Novo's Catalent buy by Dec. 6
EU antitrust regulators will decide by Dec. 6 whether to clear Novo Holdings' acquisition of contract drug manufacturer Catalent , according to a filing on the European Commission website on Monday.
Roche comes out against clearing takeover of drug manufacturer Catalent
The CEO of pharmaceuticals giant Roche has urged authorities to block the takeover of contract drug manufacturer Catalent by Novo Nordisk's controlling shareholder, citing harm to industry peers.
Catalent CEO to remain in charge of contract drugmaker after Novo Holdings' buyout
Catalent president and CEO Alessandro Maselli said on Monday he will stay on as the contract drugmaker's chief after it is acquired by Novo Holdings, the controlling shareholder of weight-loss drug ma...
Catalent Issues Open Letter to Customers Regarding Pending Acquisition by Novo Holdings
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today issued the following open letter to c...
Consumer groups ask FTC to block Novo Holdings-Catalent deal
Five U.S. consumer groups and two large labor unions urged the U.S. Federal Trade Commission on Thursday to block Novo Nordisk's controlling shareholder from acquiring contract drug manufacturer Catal...
Catalent to sell New Jersey facility
Catalent has agreed to sell its oral drug development and small-scale manufacturing facility in Somerset, New Jersey to private contract drug manufacturer Ardena, the companies said on Monday.
Ardena Signs Agreement to Expand US Footprint with the Acquisition of Advanced Drug Product Manufacturing Facility from Catalent
Ghent, Belgium, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Ardena, a specialist pharmaceutical Contract Development and Manufacturing Organisation (CDMO) with GMP facilities in Belgium, Spain, the Netherlands ...
Catalent Signs Agreement to Sell Somerset, NJ Oral Solids Facility
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, announced today that it has entered into a ...
US Senator Warren calls for scrutiny of Novo Holdings' Catalent deal
U.S. Senator Elizabeth Warren has asked antitrust regulators to closely scrutinize a $16.5 billion deal in which Novo Nordisk's controlling shareholder would acquire contract drug manufacturer Catalen...
Catalent delays filing of annual report
Catalent said on Friday it was unable to file its annual report with regulators on time as it requires additional time to complete "certain processes".
Catalent beats revenue estimates ahead of deal close with Novo Nordisk parent
Contract drug manufacturer Catalent beat analysts' estimates for fourth-quarter revenue on Thursday, helped by its biologics segment that develops and manufactures cell and gene therapies.
Catalent, Inc. Reports Fourth Quarter and Fiscal 2024 Results
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced financial results for the f...